ATE312093T1 - 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren - Google Patents
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitorenInfo
- Publication number
- ATE312093T1 ATE312093T1 AT01937687T AT01937687T ATE312093T1 AT E312093 T1 ATE312093 T1 AT E312093T1 AT 01937687 T AT01937687 T AT 01937687T AT 01937687 T AT01937687 T AT 01937687T AT E312093 T1 ATE312093 T1 AT E312093T1
- Authority
- AT
- Austria
- Prior art keywords
- ylmethyliden
- pyrrol
- ylmethyl
- pyrrolidine
- protein kinase
- Prior art date
Links
- ZHMQQCWNIPWUPV-UHFFFAOYSA-N 1-(pyrrolidin-1-ylmethyl)-3-(1h-pyrrol-2-ylmethylidene)indol-2-one Chemical class C12=CC=CC=C2C(=CC=2NC=CC=2)C(=O)N1CN1CCCC1 ZHMQQCWNIPWUPV-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20700000P | 2000-05-24 | 2000-05-24 | |
US22504500P | 2000-08-11 | 2000-08-11 | |
PCT/US2001/016756 WO2001090104A2 (en) | 2000-05-24 | 2001-05-24 | -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE312093T1 true ATE312093T1 (de) | 2005-12-15 |
Family
ID=26901875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01939357T ATE333453T1 (de) | 2000-05-24 | 2001-05-24 | Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren |
AT01937687T ATE312093T1 (de) | 2000-05-24 | 2001-05-24 | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01939357T ATE333453T1 (de) | 2000-05-24 | 2001-05-24 | Mannich base prodrugs von 3-(pyrrol-2- ylmethylidene)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren |
Country Status (13)
Country | Link |
---|---|
US (8) | US6710067B2 (de) |
EP (3) | EP1283835A2 (de) |
JP (3) | JP2003534342A (de) |
AR (3) | AR033977A1 (de) |
AT (2) | ATE333453T1 (de) |
AU (3) | AU2001264877A1 (de) |
CA (3) | CA2408709A1 (de) |
DE (2) | DE60116487T2 (de) |
ES (2) | ES2253385T3 (de) |
HK (2) | HK1054552B (de) |
MY (2) | MY128449A (de) |
TW (1) | TWI270545B (de) |
WO (3) | WO2001090104A2 (de) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051593A (en) * | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
US20030153015A1 (en) * | 2000-01-20 | 2003-08-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU3977001A (en) | 2000-02-15 | 2001-08-27 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
TWI270545B (en) * | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
EP1294688A2 (de) * | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinon derivate als protein kinase/phosphatase inhibitoren |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
WO2002081466A1 (en) * | 2001-04-09 | 2002-10-17 | Sugen, Inc. | Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
PE20030062A1 (es) | 2001-05-30 | 2003-02-08 | Sugen Inc | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas |
WO2003000251A1 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel idolinones and uses thereof |
CA2452392A1 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
EP1401412A2 (de) * | 2001-06-29 | 2004-03-31 | AB Science | Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
EP1450775B1 (de) * | 2001-09-20 | 2008-03-12 | AB Science | C-kithemmer zur behandlung von bakteriellen infektionen |
MXPA04003385A (es) | 2001-10-10 | 2005-04-11 | Sugen Inc | Derivados de 3-?4-substituido con heterociclilo)-pirrol-2-ilmetilidene?-2-indolinona como inhibidores de cinasa. |
EP1453502A4 (de) * | 2001-11-21 | 2007-01-10 | Sugen Inc | Pharmazeutische formulierungen mit indolinon-derivaten |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
WO2003057165A2 (en) * | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
EP1487452B1 (de) * | 2002-02-22 | 2006-05-24 | The Government of the United States of America, as represented by The Department of Veterans Affairs | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen |
EP1490474A4 (de) * | 2002-03-22 | 2005-05-04 | Bayer Pharmaceuticals Corp | Verfahren zur herstellung von pseudoinseln |
US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
WO2004050681A2 (en) * | 2002-11-15 | 2004-06-17 | Exelixis, Inc. | Kinase modulators |
JP4879492B2 (ja) * | 2002-11-27 | 2012-02-22 | アラーガン、インコーポレイテッド | 疾患の治療のためのキナーゼ阻害剤 |
US6747025B1 (en) | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
ES2292329B2 (es) * | 2002-11-27 | 2009-09-16 | Allergan, Inc. | Inhibidores de quinasa para el tratamiento de enfermedades. |
US6699863B1 (en) | 2002-11-27 | 2004-03-02 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
CN1747729A (zh) * | 2002-12-09 | 2006-03-15 | 得克萨斯系统大学董事会 | Janus酪氨酸激酶3(JAK3)的选择性抑制方法 |
US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2004105763A2 (en) | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
CA2762955A1 (en) * | 2003-10-16 | 2005-04-28 | Imclone Llc | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
US20050182122A1 (en) * | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
US7488817B2 (en) * | 2004-02-02 | 2009-02-10 | The Trustees Of The University Of Pennsylvania | Metal complex protein kinase inhibitors |
WO2006032164A1 (fr) * | 2004-09-23 | 2006-03-30 | Beijing Molecule Science And Technology Co., Ltd. | Dérivés de 2-indolinone substituée en position 1 et 3, préparation, composition et utilisation de ceux-ci |
CN101054379A (zh) * | 2006-04-11 | 2007-10-17 | 上海恒瑞医药有限公司 | 吡咯取代的嘧啶酮衍生物、其制备方法及其在医药上的用途 |
WO2008054605A2 (en) * | 2006-10-06 | 2008-05-08 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
WO2008115499A1 (en) * | 2007-03-19 | 2008-09-25 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon | Mannich base n-oxide drugs |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
EP2261206A4 (de) * | 2008-04-01 | 2011-08-17 | Astellas Pharma Inc | Indolinonverbindung |
US8106039B2 (en) * | 2008-04-30 | 2012-01-31 | The Trustees Of The University Of Pennsylvania | Metal complex phosphatidyl-inositol-3-kinase inhibitors |
US20120029046A1 (en) * | 2008-08-25 | 2012-02-02 | Generics (Uk) Limited | Crystalline form of sunitinib and processes for its preparation |
CA2735084A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel polymorphs of sunitinib and processes for their preparation |
EP2181991A1 (de) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Neuartige Sunitinib-Salze |
EP2186809A1 (de) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | Neue kristalline Form von Sunitinib-Malat |
EP2397139B1 (de) * | 2009-01-29 | 2014-09-17 | Hayashibara Co., Ltd. | Mittel gegen neurodegenerative erkrankungen |
WO2010087313A1 (ja) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | 神経突起伸展促進剤 |
WO2010087315A1 (ja) * | 2009-01-29 | 2010-08-05 | 株式会社林原生物化学研究所 | 抗アルツハイマー病剤 |
NZ597107A (en) | 2009-06-25 | 2013-12-20 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
ES2885698T3 (es) * | 2009-06-25 | 2021-12-15 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos nh-ácidos |
SG178279A1 (en) | 2009-08-05 | 2012-03-29 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
RU2642234C2 (ru) * | 2009-08-14 | 2018-01-24 | ОПКО Хельс, Инк. | Композиции антагонистов нейрокинина-1 для внутривенного введения |
BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
ES2691671T3 (es) * | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
EP2654797B1 (de) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Polymer-desethyl-sunitinib-konjugate |
US9827326B2 (en) | 2010-12-23 | 2017-11-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
EP2685979B1 (de) | 2011-03-18 | 2016-08-24 | Alkermes Pharma Ireland Limited | Injizierbare pharmazeutische zusammensetzungen enthaltend wasserunlösliches antipsychotisches, sorbitanlaurat und polysorbat 20 |
WO2013142198A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
EP2827866B1 (de) | 2012-03-19 | 2023-05-03 | Alkermes Pharma Ireland Limited | Pharmazeutische zusammensetzungen mit benzylalkohol |
WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US9452131B2 (en) | 2014-03-20 | 2016-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN104610231B (zh) * | 2015-01-28 | 2016-08-17 | 广州葳澜生物科技有限公司 | 一种舒尼替尼前药 |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
EP3771711A1 (de) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazolderivate für die kontrolle von arthropoden |
CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL104796C (de) | 1957-08-19 | |||
NL45080C (de) | 1935-08-22 | |||
DE683735C (de) | 1936-05-12 | 1939-11-14 | Paul Hadamovsky | Verfahren zur Kuehlung, Verfluessigung und Speicherung von Chlor und anderen aggressi Gasen |
DE878539C (de) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Verfahren zur Herstellung von Methinfarbstoffen |
BE553661A (de) | 1955-12-23 | |||
BE558210A (de) | 1956-06-08 | |||
FR1398224A (fr) | 1964-05-06 | 1965-05-07 | Ici Ltd | Procédé de teinture de matières textiles de polyacrylonitrile |
FR1599772A (de) | 1968-09-17 | 1970-07-20 | ||
DE2159360A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159361A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159363A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimikrobielle mittel |
DE2159362A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US4420639C1 (en) | 1973-09-11 | 2001-08-21 | Beecham Group Ltd | Aromatic compounds |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
US5389613A (en) | 1979-09-21 | 1995-02-14 | Roussel Uclaf | Method of treating prostate adenocarcinoma, prostate benign hypertrophia and endometriosis |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
JPS6229570A (ja) | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | 3,5−ジイソプロピルベンジリデン複素環式化合物 |
JPS6239564A (ja) | 1985-08-13 | 1987-02-20 | Kanegafuchi Chem Ind Co Ltd | α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体 |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
JPS63141955A (ja) | 1986-12-03 | 1988-06-14 | Kanegafuchi Chem Ind Co Ltd | トリベンジルアミン誘導体 |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (en) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
WO1992007830A2 (en) | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
JPH0558894A (ja) | 1991-08-27 | 1993-03-09 | Kanegafuchi Chem Ind Co Ltd | 抗腫瘍剤 |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5994362A (en) | 1992-03-11 | 1999-11-30 | Merck & Co., Inc. | Method of treatment for prostatic cancer |
FR2689397A1 (fr) | 1992-04-01 | 1993-10-08 | Adir | Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments. |
FR2694004B1 (fr) | 1992-07-21 | 1994-08-26 | Adir | Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
EP0665839A1 (de) | 1992-10-21 | 1995-08-09 | Pfizer Inc. | Enantiomerisch cis-3-(4,6-dihydroxychroman-3-yl-methyl)-benzoesäuren |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
DE59402281D1 (de) | 1993-06-28 | 1997-05-07 | Bayer Ag | Massefärben von Kunststoffen |
GB9313638D0 (en) | 1993-07-01 | 1993-08-18 | Erba Carlo Spa | Arylidene and heteroarylidene oxindole derivatives and process for their preparation |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
GB9423997D0 (en) | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5777134A (en) | 1995-10-26 | 1998-07-07 | Merck & Co., Inc. | 4-oxa and 4-thia steriods |
CA2214759C (en) | 1996-01-17 | 2004-05-18 | Taiho Pharmaceutical Co., Ltd. | Intimal hypertrophy inhibitors |
EP0788890A1 (de) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Farbstoffe und Farbstoffdonorelemente zur thermischen Farbstoffübertragungsaufzeichnung |
EP1247803A3 (de) | 1996-08-23 | 2002-10-16 | Sugen, Inc. | Indolinon-Verbindungen und deren Verwendung als Protein- Kinase-Modulatoren |
AU7622698A (en) | 1996-12-05 | 1998-06-29 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
ATE554750T1 (de) | 1997-03-05 | 2012-05-15 | Sugen Inc | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen |
ATE292623T1 (de) | 1997-05-07 | 2005-04-15 | Sugen Inc | 2-indolinonderivate als modulatoren der proteinkinase-ativität |
AU7723198A (en) | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
WO2000008202A2 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
DE19816624A1 (de) | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
NZ508815A (en) | 1998-05-29 | 2005-02-25 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
DE19826940A1 (de) | 1998-06-17 | 1999-12-23 | Bayer Ag | Substituierte N-Aryl-O-alkyl-carbamate |
JP2002532490A (ja) | 1998-12-17 | 2002-10-02 | エフ.ホフマン−ラ ロシュ アーゲー | 4−および5−アルキニルオキシンドールと4−および5−アルケニルオキシンドール |
KR100649925B1 (ko) | 1998-12-17 | 2007-02-28 | 에프. 호프만-라 로슈 아게 | 싸이클린-의존성 키나제, 특히 cdk2 의 저해제로서4-알케닐 (및 알키닐) 옥신돌 |
CA2354591A1 (en) | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4-aryloxindoles as inhibitors of jnk protein kinases |
CA2357042A1 (en) | 1998-12-31 | 2000-07-06 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
CA2368041A1 (en) | 1999-03-24 | 2000-09-28 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
AU3977001A (en) | 2000-02-15 | 2001-08-27 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
TWI270545B (en) * | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
AU2001268213B2 (en) * | 2000-06-07 | 2005-11-10 | Ortho-Mcneil Pharmaceutical, Inc. | Method to detect modulators of vegf kinase domain |
-
2001
- 2001-05-23 TW TW090112409A patent/TWI270545B/zh not_active IP Right Cessation
- 2001-05-23 MY MYPI20012452A patent/MY128449A/en unknown
- 2001-05-23 MY MYPI20012435A patent/MY128450A/en unknown
- 2001-05-24 AR ARP010102490A patent/AR033977A1/es unknown
- 2001-05-24 JP JP2001586291A patent/JP2003534342A/ja active Pending
- 2001-05-24 AT AT01939357T patent/ATE333453T1/de not_active IP Right Cessation
- 2001-05-24 JP JP2001586257A patent/JP2003534323A/ja not_active Withdrawn
- 2001-05-24 AU AU2001264877A patent/AU2001264877A1/en not_active Abandoned
- 2001-05-24 AR ARP010102489A patent/AR041775A1/es unknown
- 2001-05-24 AT AT01937687T patent/ATE312093T1/de not_active IP Right Cessation
- 2001-05-24 US US09/863,804 patent/US6710067B2/en not_active Expired - Fee Related
- 2001-05-24 WO PCT/US2001/016756 patent/WO2001090104A2/en active IP Right Grant
- 2001-05-24 US US09/863,819 patent/US6482848B2/en not_active Expired - Fee Related
- 2001-05-24 JP JP2001586290A patent/JP2003534341A/ja not_active Withdrawn
- 2001-05-24 EP EP01939349A patent/EP1283835A2/de not_active Ceased
- 2001-05-24 AU AU2001263399A patent/AU2001263399A1/en not_active Abandoned
- 2001-05-24 EP EP01937687A patent/EP1294711B8/de not_active Expired - Lifetime
- 2001-05-24 DE DE60116487T patent/DE60116487T2/de not_active Expired - Fee Related
- 2001-05-24 AR ARP010102488A patent/AR042383A1/es unknown
- 2001-05-24 ES ES01937687T patent/ES2253385T3/es not_active Expired - Lifetime
- 2001-05-24 US US09/863,905 patent/US6451838B1/en not_active Expired - Fee Related
- 2001-05-24 DE DE60121595T patent/DE60121595T2/de not_active Expired - Fee Related
- 2001-05-24 WO PCT/US2001/016741 patent/WO2001090103A2/en not_active Application Discontinuation
- 2001-05-24 WO PCT/US2001/016757 patent/WO2001090068A2/en active IP Right Grant
- 2001-05-24 CA CA002408709A patent/CA2408709A1/en not_active Abandoned
- 2001-05-24 CA CA002409430A patent/CA2409430A1/en not_active Abandoned
- 2001-05-24 ES ES01939357T patent/ES2269416T3/es not_active Expired - Lifetime
- 2001-05-24 EP EP01939357A patent/EP1301507B1/de not_active Expired - Lifetime
- 2001-05-24 AU AU2001264885A patent/AU2001264885A1/en not_active Abandoned
- 2001-05-24 CA CA002409367A patent/CA2409367A1/en not_active Abandoned
-
2002
- 2002-09-16 US US10/243,663 patent/US20030045565A1/en not_active Abandoned
- 2002-09-16 US US10/243,942 patent/US6716870B2/en not_active Expired - Fee Related
-
2003
- 2003-05-05 US US10/429,895 patent/US7008943B2/en not_active Expired - Fee Related
- 2003-09-22 HK HK03106800.4A patent/HK1054552B/zh not_active IP Right Cessation
- 2003-09-24 HK HK03106876A patent/HK1054741A1/xx not_active IP Right Cessation
- 2003-12-24 US US10/743,909 patent/US7053113B2/en not_active Expired - Fee Related
-
2004
- 2004-02-10 US US10/774,415 patent/US7112603B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE312093T1 (de) | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2- ylmethyliden)-2-indolinon derivate und deren verwendung als protein kinase inhibitoren | |
ATE419849T1 (de) | Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren | |
ATE430754T1 (de) | Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren | |
EE200300385A (et) | 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid | |
DE60221233D1 (de) | Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren | |
ATE445613T1 (de) | Indolylmaleimidderivative als proteinkinase-c- inhibitoren | |
ATE394102T1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
ATE299881T1 (de) | 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren | |
DE60113719D1 (de) | Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten | |
DE69833223D1 (de) | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen | |
DE60208661D1 (de) | Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren | |
DE59908600D1 (de) | Substituierte benzimidazole und ihre verwendung als parp inhibitoren | |
ATE343565T1 (de) | Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten | |
DE50015651D1 (de) | Cycloalkylsubstituierte benzimidazole und ihre verwendung als parp inhibitoren | |
DE50311397D1 (de) | Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren | |
ATE316527T1 (de) | Substituierte indolinone als tyrosinkinase inhibitoren | |
ATE282593T1 (de) | Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren | |
DE69711020T2 (de) | Thiazole derivate als protein kinase c inhibitoren | |
DE50105955D1 (de) | Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren | |
DE69717647T2 (de) | 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen | |
ATE520399T1 (de) | Aminoindazole derivate als kinase inhibitoren | |
DE60202131D1 (de) | Naphthostyril derivate und deren verwendung als inhibitoren von cyclin-abhängigen kinasen | |
NO20031698D0 (no) | Krystallformer av 1-(6-klor-5-(trifluormetyl)-2- pyridinyl)piperazin-hydroklorid | |
ATE403652T1 (de) | Imidazolderivate und deren verwendung als peripheral-selektive inhibitoren von dopamin-beta-hydroxylasen | |
IL172840A (en) | Benzimidazole history and their use as a protein kinase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |